Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs [Yahoo! Finance]
Cyclacel Pharmaceuticals, Inc. (CYCC)
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cyclacel.com/investor-relations
Company Research
Source: Yahoo! Finance
biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company's cash, including a potential transaction with investor David Lazar of Activist Investing, LLC, which transaction would be subject to the consent of an existing securityholder. The Company's Board of Directors is reviewing a range of appropriate strategies to realize value from its assets. The Board has directed management to reduce operating costs while such alternatives are being explored. There can be no assurance that the exploration of strategic alternatives will result in any agreement or transaction, or as to the timing of any such agreement or transaction. Further, there can be no assurance that the Company will be able to reach an agreement, or consummate a transaction, with Mr. Lazar or receive the required consent of an existing securityholder to any such transac
Show less
Read more
Impact Snapshot
Event Time:
CYCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYCC alerts
High impacting Cyclacel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CYCC
News
- David Lazar acquires Cyclacel Pharmaceuticals preferred stock, becomes interim CEO; stock jumps [Seeking Alpha]Seeking Alpha
- Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David LazarGlobeNewswire
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
CYCC
Earnings
- 11/12/24 - Beat
CYCC
Sec Filings
- 1/6/25 - Form 8-K
- 12/12/24 - Form 8-K
- 11/26/24 - Form D
- CYCC's page on the SEC website